SCHEMBL4514645

SCHEMBL4514645

CCOC(=O)c1ccc(NC(=O)Nc2ccc(CC3CCN(C4CCC(C)(O)CC4)C3=O)c(Cl)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.44
MAPT P10636 11/20 0.42
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
CASP3 P42574 2/20 0.42
SENP7 Q9BQF6 2/20 0.42
LMNA P02545 2/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
GAA P10253 3/20 0.41
TP53 P04637 2/20 0.40
RAB9A P51151 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NAMPT P43490 1/20 0.39
ABL1 P00519 1/20 0.38
HTT P42858 1/20 0.38
RIN1 Q13671 1/20 0.38
ALDH1A1 P00352 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4511065 0.89 EPHX2 (0.36) MAPTMEN1KMT2ACASP3SENP7
SCHEMBL5548898 0.84 RORC (0.39) MAPTSMN1; SMN2ALDH1A1
SCHEMBL4501026 0.82 HSD11B1 (0.48) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL4505621 0.82 NPY2R (0.36) MAPTMEN1KMT2AALDH1A1
SCHEMBL4514917 0.82 KMT2A (0.42) MAPTMEN1KMT2ALMNAUSP2
SCHEMBL4514423 0.82 CHRM1 (0.43) MAPTKMT2ALMNAMAPK1TP53
SCHEMBL4505657 0.81 EPHX2 (0.41) GAASMN1; SMN2
SCHEMBL13674531 0.79 BMPR1B (0.38) MEN1KMT2ASMN1; SMN2HTTALDH1A1
SCHEMBL4528168 0.79 BMPR1B (0.38) MEN1KMT2ASMN1; SMN2HTTALDH1A1
SCHEMBL4514431 0.79 KMT2A (0.44) MAPTMEN1KMT2ALMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 TRPV1 3739/4885MAPT 4692/4885MEN1 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.